United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $485.43, for a total value of $4,029,069.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $17,854,600.83. This trade represents a 18.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Price Performance

Shares of UTHR opened at $496.72 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The business’s fifty day moving average price is $478.35 and its 200 day moving average price is $394.39. The stock has a market capitalization of $21.39 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 4.68 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the firm posted $6.39 earnings per share. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on UTHR. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Oppenheimer upped their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the stock. CWM LLC raised its holdings in United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 3,487 shares in the last quarter. AXQ Capital LP increased its holdings in United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares during the period. Osaic Holdings Inc. raised its stake in shares of United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after buying an additional 33,662 shares in the last quarter. Simplify Asset Management Inc. bought a new position in United Therapeutics during the third quarter worth about $8,351,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in United Therapeutics by 77.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock valued at $1,792,000 after purchasing an additional 2,655 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.